Foamix Pharmaceuticals Ltd. (FOMX) Downgraded by Zacks Investment Research to “Sell”
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.
According to Zacks, “Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company’s lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel. “
Several other research analysts also recently commented on the stock. HC Wainwright initiated coverage on shares of Foamix Pharmaceuticals in a research note on Thursday, August 24th. They set a “buy” rating and a $12.00 price target on the stock. Credit Suisse Group reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Foamix Pharmaceuticals in a research note on Wednesday, July 19th.
Shares of Foamix Pharmaceuticals (NASDAQ:FOMX) remained flat at $5.50 during trading on Tuesday. The company’s stock had a trading volume of 122,945 shares. The firm has a 50 day moving average of $5.14 and a 200 day moving average of $5.00. Foamix Pharmaceuticals has a one year low of $4.03 and a one year high of $11.27. The stock’s market capitalization is $205.84 million.
Foamix Pharmaceuticals (NASDAQ:FOMX) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.05). Foamix Pharmaceuticals had a negative return on equity of 39.20% and a negative net margin of 823.74%. The firm had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $1.50 million. During the same period in the prior year, the company earned ($0.27) EPS. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. On average, equities research analysts forecast that Foamix Pharmaceuticals will post ($1.53) EPS for the current year.
WARNING: “Foamix Pharmaceuticals Ltd. (FOMX) Downgraded by Zacks Investment Research to “Sell”” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/04/foamix-pharmaceuticals-ltd-fomx-downgraded-by-zacks-investment-research-to-sell.html.
Several institutional investors and hedge funds have recently added to or reduced their stakes in FOMX. Baird Financial Group Inc. purchased a new position in shares of Foamix Pharmaceuticals in the first quarter worth about $188,000. AXA increased its stake in Foamix Pharmaceuticals by 19.3% in the 1st quarter. AXA now owns 826,437 shares of the specialty pharmaceutical company’s stock worth $4,091,000 after purchasing an additional 133,602 shares during the period. MARSHALL WACE ASIA Ltd purchased a new position in Foamix Pharmaceuticals in the 1st quarter worth approximately $2,217,000. Marshall Wace North America L.P. purchased a new position in Foamix Pharmaceuticals in the 1st quarter worth approximately $2,217,000. Finally, Renaissance Technologies LLC purchased a new position in Foamix Pharmaceuticals in the 1st quarter worth approximately $307,000. Hedge funds and other institutional investors own 57.60% of the company’s stock.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.
Receive News & Stock Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related stocks with our FREE daily email newsletter.